Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Change in Receivables: 2015-2025

Historic Change in Receivables for Editas Medicine (EDIT) over the last 10 years, with Sep 2025 value amounting to $7.5 million.

  • Editas Medicine's Change in Receivables rose 6491.53% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year increase of 448.61%. This contributed to the annual value of $6.1 million for FY2024, which is 20.57% up from last year.
  • Editas Medicine's Change in Receivables amounted to $7.5 million in Q3 2025, which was up 9,569.23% from $78,000 recorded in Q2 2025.
  • Over the past 5 years, Editas Medicine's Change in Receivables peaked at $16.1 million during Q4 2024, and registered a low of -$15.8 million during Q1 2025.
  • In the last 3 years, Editas Medicine's Change in Receivables had a median value of $78,000 in 2025 and averaged $271,364.
  • Its Change in Receivables has fluctuated over the past 5 years, first slumped by 1,133.33% in 2021, then skyrocketed by 31,306.25% in 2022.
  • Editas Medicine's Change in Receivables (Quarterly) stood at $16,000 in 2021, then soared by 31,306.25% to $5.0 million in 2022, then skyrocketed by 54.53% to $7.8 million in 2023, then surged by 107.86% to $16.1 million in 2024, then soared by 6,491.53% to $7.5 million in 2025.
  • Its Change in Receivables stands at $7.5 million for Q3 2025, versus $78,000 for Q2 2025 and -$15.8 million for Q1 2025.